Prostate cancer genetic alterations in Hispanic men

Abstract

BackgroundDifferences in DNA alterations in prostate cancer among White, Black, and Asian men have been widely described. This is the first description of the frequency of DNA alterations in primary and metastatic prostate cancer samples of self‐reported Hispanic men.MethodsWe utilized targeted next‐generation sequencing tumor genomic profiles from prostate cancer tissues that underwent clinical sequencing at academic centers (GENIE 11th). We decided to restrict our analysis to the samples from Memorial Sloan Kettering Cancer Center as it was by far the main contributor of Hispanic samples. The numbers of men by self‐reported ethnicity and racial categories were analyzed via Fisher's exact test between Hispanic‐White versus non‐Hispanic White.Results and LimitationsOur cohort consisted of 1412 primary and 818 metastatic adenocarcinomas. In primary adenocarcinomas, TMPRSS2 and ERG gene alterations were less common in non‐Hispanic White men than Hispanic White (31.86% vs. 51.28%, p = 0.0007, odds ratio [OR] = 0.44 [0.27–0.72] and 25.34% vs. 42.31%, p = 0.002, OR = 0.46 [0.28–0.76]). In metastatic tumors, KRAS and CCNE1 alterations were less prevalent in non‐Hispanic White men (1.03% vs. 7.50%, p = 0.014, OR = 0.13 [0.03, 0.78] and 1.29% vs. 10.00%, p = 0.003, OR = 0.12 [0.03, 0.54]). No significant differences were found in actionable alterations and androgen receptor mutations between the groups. Due to the lack of clinical characteristics and genetic ancestry in this dataset, correlation with these could not be explored.ConclusionDNA alteration frequencies in primary and metastatic prostate cancer tumors differ among Hispanic‐White and non‐Hispanic White men. Notably, we found no significant differences in the prevalence of actionable genetic alterations between the groups, suggesting that a significant number of Hispanic men could benefit from the development of targeted therapies.

Genomic ancestry and cancer among Latin Americans

“…With targeted next-generation sequencing under the GENIE 11th model, Arenas-Gallo et al evaluated 1412 primary and 818 metastatic prostate adenocarcinomas, including Latin American men [ 96 ]. The study determined that TMPRSS2 and ERG gene alterations in primary tumors were more common among Latin Americans (51.28%; OR 0.44 95% CI 0.27–0.72).…”

“…The study determined that TMPRSS2 and ERG gene alterations in primary tumors were more common among Latin Americans (51.28%; OR 0.44 95% CI 0.27–0.72). On the other hand, in metastatic tumors, KRAS and CCNE1 alterations were less prevalent in non-Hispanic White men, and no significant differences were found in actionable alterations and androgen receptor mutations between the groups [ 96 ]. Developing a retrospective analysis, The Hispanic Americans Prostate Cancer Comprehensive Genomic Profiling Study (THAPCA-GPS) examined 190 patients with metastatic prostate adenocarcinoma.…”

Genomic Landscape of Early-Stage Prostate Adenocarcinoma in Mexican patients: An exploratory study

“…However, very little genetic information can be found about Hispanics patients. The rst description of the frequency of DNA alterations in primary and metastatic prostate cancer of Hispanic men, published in 2023, identi ed a higher frequency of TMPRSS2, ERG, and PPARG alterations in Hispanic men than non-Hispanic men but no differences in the prevalence of actionable genetic alterations were found between Hispanic and non-Hispanic patients [9]. Among the Hispanic community, Mexican men present a more aggressive disease with an advanced stage at diagnosis and mortality rates are higher compared to other Hispanic American and No-Hispanic White men [10].…”